2 Days
Source:
عدن تايم
Source: عدن تايم
2 Daysعدن تايم
Source: عدن تايم
2 DaysReady to play
Ready to play
A Phase 3 clinical trial has shown that a single dose of lisergaid may help reduce symptoms of generalized anxiety disorder for up to 12 weeks. The study involved 245 adults aged 18 to 74 suffering from generalized anxiety disorder, with results indicating that participants who received a 100-microgram dose experienced a significant decrease in anxiety levels, starting from day two and continuing throughout the follow-up period. The proportion of participants achieving a 50% reduction in symptoms was 32% in the treatment group compared to 14% in the placebo group, suggesting potential for future use as a new treatment option for these symptoms, although the results still require further regulatory review before official approval.
Notice: This Is an AI-Generated Summary
Comments (0)